Drug Profile
Research programme: peptide therapeutics - BTG
Alternative Names: Peptide therapy - BTGLatest Information Update: 21 Aug 2019
Price :
$50
*
At a glance
- Originator BTG
- Class
- Mechanism of Action Peptide stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Coeliac disease
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 16 Jul 2016 No recent reports of development identified for preclinical development in Coeliac disease in United Kingdom
- 05 Jun 2007 Nexpep Pty Ltd. has an option to license the peptide therapeutics